Use of FibroScan? with Controlled Attenuation Parameter to Estimate the Prevalence of NAFLD with Advanced Fibrosis in Patients with or without Metabolic Syndrome
Study on NAFLD and How We Measure Liver Fat
Brief description of study.
The purpose of this study are to prospectively estimate the prevalence of NAFLD with or without advanced fibrosis in patients with or without metabolic syndrome using FibroScan? with CAP and to examine the relationship between hepatic steatosis measured using CAP and steatosis graded by liver histology and with actual measurement of hepatic triglyceride content in patients where liver histology is available.
Detailed description of study
The purpose of this study are to prospectively estimate the prevalence of NAFLD with or without advanced fibrosis in patients with or without metabolic syndrome using FibroScan? with CAP and to examine the relationship between hepatic steatosis measured using CAP and steatosis graded by liver histology and with actual measurement of hepatic triglyceride content in patients where liver histology is available.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: NAFLD
-
Age: 100 years or below
-
Gender: All
This study investigates the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in individuals with or without metabolic syndrome. Metabolic syndrome is a group of conditions that occur together, increasing the risk of heart disease, stroke, and type 2 diabetes. The study uses a device called FibroScan with Controlled Attenuation Parameter (CAP) to measure liver fat and compares it to traditional liver biopsy results.
Participants will undergo a FibroScan, which is a painless procedure similar to an ultrasound, to assess liver fat. In some cases, participants may also have a liver biopsy, which involves taking a small sample of liver tissue to examine under a microscope. The study aims to compare these two methods of measuring liver fat content.
- Who can participate: Adults aged 18 and over with or without metabolic syndrome are eligible. Participants may have varying degrees of liver fat and fibrosis.
- Study details: Participants will undergo a FibroScan to measure liver fat. In some cases, a liver biopsy may also be conducted to compare results.
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or